Drugs / Mono-dgA-RFB4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00007956 | Nov 2000 → ? | lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mono-dgA-RFB4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00007956 ↗ |
| Modality | Monoclonal antibody | “Patients receive monoclonal antibody Mono-dgA-RFB4 IV over 4 hours on days 1, 3, and 5.” NCT00007956 ↗ |
| Route | Intravenous | “Mono-dgA-RFB4 IV over 4 hours” NCT00007956 ↗ |
| Target | CD22 | “CD22 binding agent” CHEMBL2109354 ↗ |